Can mirtazapine (Remeron) cause or worsen restless legs syndrome, and how should it be managed?

Mirtazapine (Remeron) Can Cause or Worsen Restless Legs Syndrome

Mirtazapine is associated with a significant risk of causing or worsening restless legs syndrome (RLS), with evidence showing it provokes or deteriorates RLS in approximately 28% of patients—the highest rate among commonly used antidepressants. If a patient develops RLS while taking mirtazapine, the medication should be discontinued and replaced with an alternative antidepressant that does not exacerbate RLS 1.

Evidence for Mirtazapine-Induced RLS

The relationship between mirtazapine and RLS is well-documented in the literature:

• Prospective observational data from neurological practices found that mirtazapine caused or worsened RLS in 28% of patients, the highest rate among second-generation antidepressants studied. By comparison, other selective antidepressants ranged from 5-10%, while reboxetine caused no cases 1.

• RLS symptoms typically emerge within the first week of mirtazapine initiation, with a mean onset of approximately 7.5 days 2.

• A systematic review confirmed that among various antidepressants, mirtazapine may be associated with higher rates of RLS and periodic limb movements compared to other agents 3.

• Case reports document clear temporal relationships between mirtazapine initiation and RLS onset, with symptom resolution upon drug discontinuation 4, 5.

Management Algorithm

If RLS Develops on Mirtazapine:

1. Discontinue mirtazapine immediately 2, 1

   • Do not attempt dose adjustment or splitting
   • Symptoms typically improve within one week of discontinuation in 82.6% of cases 2

2. Switch to an alternative antidepressant with lower RLS risk:

   • Bupropion is the preferred choice—it may actually reduce RLS symptoms due to its dopaminergic activity and lack of serotonergic effects 6, 3, 5
   • Sertraline or fluoxetine are reasonable alternatives, though they may cause minor increases in periodic limb movements that are typically not clinically significant 3
   • Avoid other antidepressants with high serotonergic activity

3. Check iron status before initiating RLS-specific treatment:

   • Measure ferritin and transferrin saturation
   • If ferritin <75 ng/mL or transferrin saturation <20%, provide iron supplementation 6, 7

4. If RLS persists after mirtazapine discontinuation, initiate RLS-specific treatment per AASM 2025 guidelines:

   • First-line options (strong recommendations): gabapentin enacarbil, gabapentin, or pregabalin 6
   • Second-line options: IV iron formulations if iron deficient, or extended-release opioids 6
   • Avoid dopamine agonists as standard treatment due to augmentation risk 6

Important Clinical Caveats

Do not rechallenge with mirtazapine if RLS develops—the risk of recurrence is high and alternative effective antidepressants are available 2.

Timing matters: RLS symptoms typically appear within days of starting mirtazapine, so early recognition allows for prompt intervention before symptoms become severe 2, 1.

The FDA label for Remeron does not specifically list RLS as an adverse effect 8, but postmarketing surveillance and clinical research clearly establish this association. The label does note somnolence and other neurological effects that may overlap with RLS presentation 8.

Distinguish RLS from akathisia: While both can occur with mirtazapine, they require different management. RLS has characteristic circadian worsening in the evening/night and relief with movement, while akathisia is more constant restlessness without circadian pattern 2.

Why Mirtazapine Causes RLS

The mechanism likely involves mirtazapine's antagonism of 5-HT2A and 5-HT2C receptors, which may disrupt dopaminergic pathways involved in RLS pathophysiology 2. This serotonergic activity explains why bupropion (which lacks serotonergic effects and enhances dopamine) can reverse mirtazapine-induced RLS 5.